GURU.Markets stock price, segment price, and overall market index valuation
The company's share price bioAffinity Technologies
bioAffinity Technologies develops noninvasive tests for the early detection of lung cancer. Its stock price is a bet on the success of its technology. The stock price reflects high volatility and dependence on news about clinical data and commercialization.
Share prices of companies in the market segment - Lungs' cancer
bioAffinity Technologies is developing noninvasive tests for the early detection of lung cancer using sputum analysis. We've categorized it under "Lung Cancer," and the chart below shows how investors value companies working to improve cancer screening.
Broad Market Index - GURU.Markets
bioAffinity Technologies is a biotech company developing a non-invasive test for the early detection of lung cancer. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the diagnostics sector.
Change in the price of a company, segment, and market as a whole per day
BIAF - Daily change in the company's share price bioAffinity Technologies
For bioAffinity Technologies, Inc., a lung cancer diagnostics company, daily volatility reflects sensitivity to news about the rollout of its tests. This metric is an indicator of demand for non-invasive diagnostic methods.
Daily change in the price of a set of shares in a market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. The oncology diagnostics sector is extremely sensitive to clinical trial results. The chart below shows the volatility in this niche, reflecting the high expectations and risks associated with medical breakthroughs.
Daily change in the price of a broad market stock, index - GURU.Markets
bioAffinity Technologies is a biotech company developing non-invasive tests for the early detection of lung cancer. Its shares are buoyed by anticipation of clinical trial results. These sharp movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization bioAffinity Technologies
For bioAffinity Technologies, the year's performance is a story about the development of its noninvasive test for the early detection of lung cancer. Its 12-month market cap is entirely dependent on the success of the commercialization of its CyPath® Lung test. Each new contract with a laboratory or insurance company is a fundamental step toward widespread adoption.
Annual dynamics of market capitalization of the market segment - Lungs' cancer
As an early-stage biotech company, bioAffinity is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about its non-invasive lung cancer diagnostic test. Its stock price will reflect investors' speculative belief in its potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
bioAffinity Technologies develops noninvasive tests for the early detection of lung cancer using fluorescence microscopy. Its year-over-year market capitalization is a story of how one breakthrough diagnostic technology can change the prognosis for millions of patients and create enormous shareholder value.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization bioAffinity Technologies
bioAffinity is a biotech company developing noninvasive tests for cancer diagnostics. Its monthly performance reflects progress in the commercialization of its lung cancer test. News about its clinical implementation and trial data are key.
Monthly dynamics of market capitalization of the market segment - Lungs' cancer
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. The company's success depends on the test's accuracy and its implementation in clinical practice. The dynamics of the medical diagnostics sector reflect the overall trend toward early screening, which is a tailwind for bioAffinity.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer. This is a critically important area of medicine. The company's stock price is not dependent on the market, but is driven by clinical trial results and successful commercialization. The chart reflects investor hopes for a breakthrough in cancer diagnostics.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization bioAffinity Technologies
bioAffinity Technologies is developing a non-invasive test for the early detection of lung cancer. Its weekly stock price performance reflects progress toward commercialization. News about clinical trials and FDA decisions are key drivers.
Weekly dynamics of market capitalization of the market segment - Lungs' cancer
bioAffinity Technologies is developing a non-invasive test for the early detection of lung cancer. The company's success depends entirely on clinical validation of its test's effectiveness and its commercialization. The chart shows how its shares perform within their own news cycle, independent of the market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
bioAffinity Technologies is developing a test for the early detection of lung cancer. Its shares are a bet on the success of its medical technology. The chart clearly shows how its performance is detached from the broader market and driven by news of clinical validation.
Market capitalization of the company, segment and market as a whole
BIAF - Market capitalization of the company bioAffinity Technologies
bioAffinity Technologies' market capitalization chart reflects investors' bets on its noninvasive lung cancer diagnostic test. Its dynamics reflect the market's belief that sputum analysis using its fluorescence technology will be able to detect cancer at an early stage. Its value reflects the company's enormous potential market and the high risk of commercialization.
BIAF - Share of the company's market capitalization bioAffinity Technologies within the market segment - Lungs' cancer
bioAffinity Technologies is developing a non-invasive test for the early detection of lung cancer based on sputum analysis. Its market share in the medical technology sector is small, but it is targeting a huge market. Its capitalization is a bet on its technology, which could make screening more accessible and simple.
Market capitalization of the market segment - Lungs' cancer
This chart shows the overall market capitalization of the entire oncology sector, particularly the diagnostics segment. For bioAffinity, with its early lung cancer detection test, this line is a map of the future. The rising chart reflects the global trend toward early diagnosis, which is key to successful cancer treatment, where the company is seeking its niche.
Market capitalization of all companies included in a broad market index - GURU.Markets
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer using sputum analysis. Its market capitalization is the valuation of its diagnostic technology. This represents the market share of the company's efforts to detect one of the most deadly cancers early.
Book value capitalization of the company, segment and market as a whole
BIAF - Book value capitalization of the company bioAffinity Technologies
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. Its book value is its scientific and financial capital. It consists of funds allocated for research and commercialization of its CyPath test. How has this capital changed? The chart below shows.
BIAF - Share of the company's book capitalization bioAffinity Technologies within the market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive tests for lung cancer diagnosis. Its technology requires physical infrastructure: certified laboratories for sample analysis and R&D centers for further development. The chart shows its share of the physical assets underlying early cancer diagnosis.
Market segment balance sheet capitalization - Lungs' cancer
bioAffinity is a diagnostics company. Compared to the capital-intensive healthcare sector, its model is knowledge-intensive. The industry's asset chart reflects the value of hospitals. bioAffinity, on the other hand, invests in laboratories and AI to create its tests.
Book value of all companies included in the broad market index - GURU.Markets
bioAffinity Technologies' assets are not drugs, but rather a laboratory and technology for non-invasive early-stage lung cancer diagnosis using sputum analysis. The book value reflects the resources needed to develop and commercialize this promising test. The chart illustrates its scale.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - bioAffinity Technologies
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer. Its market value is determined by its technology and its potential to save lives by making diagnosis simpler and more accessible.
Market to book capitalization ratio in a market segment - Lungs' cancer
bioAffinity Technologies is developing a non-invasive test for the early detection of lung cancer. The chart shows the high premium investors are paying for its potential to save lives and capture the huge screening market, despite the technology still being in its early stages.
Market to book capitalization ratio for the market as a whole
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. Its market value is a bet on the success of its technology. This chart shows how highly investors value breakthrough diagnostic methods that have the potential to save millions of lives and capture a huge market.
Debts of the company, segment and market as a whole
BIAF - Company debts bioAffinity Technologies
bioAffinity, a company developing a non-invasive test for the early detection of lung cancer, is raising capital to conduct extensive clinical trials and prepare for commercialization. This chart shows the enormous financial costs associated with bringing a new diagnostic product to market that must prove its accuracy.
Market segment debts - Lungs' cancer
bioAffinity Technologies is developing noninvasive diagnostic tests for the early detection of cancer, starting with lung cancer, using sputum analysis. This chart shows how the company is funding its early-stage clinical trials and R&D, striving to create a simple and affordable screening method that could save lives.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio bioAffinity Technologies
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. Commercializing such a test requires significant investment in clinical validation studies and marketing. This chart shows how the company is using debt to finance its path to market in the important field of oncology diagnostics.
Market segment debt to market segment book capitalization - Lungs' cancer
bioAffinity Technologies is developing noninvasive tests for the early detection of lung cancer using sputum analysis. This is an important medical objective. This chart shows how the company finances its research and development. It compares its debt to the market capitalization of the entire medical diagnostics sector.
Debt to book value of all companies in the market
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. Medical diagnostics is a knowledge-intensive industry, requiring massive investments in research and clinical trials. How reliant is the company on debt? This chart of total market debt provides context for assessing its financial strategy.
P/E of the company, segment and market as a whole
P/E - bioAffinity Technologies
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer, particularly lung cancer, using sputum analysis. This chart shows how investors value its technology. This assessment depends on the results of clinical trials and the acceptance of its tests by the medical community.
P/E of the market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive diagnostic tests for the early detection of cancer, particularly lung cancer, by analyzing sputum samples. This chart illustrates the average valuation in the oncology diagnostics sector, where investors highly value the potential of tests capable of detecting cancer at an early stage.
P/E of the market as a whole
bioAffinity Technologies develops non-invasive diagnostic tests for the early detection of cancer. Its first product is designed to diagnose lung cancer using sputum analysis. This chart reflects overall investor interest in the healthcare sector. It helps understand whether BIAF's valuation reflects confidence in its diagnostic platform or general market trends.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company bioAffinity Technologies
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. The company's success depends on the accuracy and acceptance of this test by doctors. This chart demonstrates the investors' confidence in the commercial potential of this simple and affordable screening method, which could save countless lives.
%20P%2FE%20bioAffinity%20Technologies&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-bioAffinity-Technologies&v=1772567384350 "Chart of the company's future (projected) P/E bioAffinity Technologies")
Future (projected) P/E of the market segment - Lungs' cancer
bioAffinity Technologies is developing a non-invasive test for the early diagnosis of lung cancer based on sputum analysis. Early detection is key to successful treatment. The graph shows average profitability expectations in the sector, helping to understand how highly the market values the life-saving potential of this technology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Lungs-cancer&v=1772567384359 "Future (projected) P/E graph of the market segment - Lungs' cancer")
Future (projected) P/E of the market as a whole
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. Early detection is key to successful treatment. This risk appetite chart shows how willing investors are to invest in companies whose technologies could save lives but require lengthy and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772567384364 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit bioAffinity Technologies
bioAffinity Technologies develops noninvasive tests for the early detection of lung cancer. Its first product analyzes sputum for cancer cells. Revenue depends on the commercial success of this test. This chart shows the company's financial trajectory as it strives to offer a simpler and more accessible method for screening for this deadly disease.
Profit of companies in the market segment - Lungs' cancer
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer, particularly lung cancer, by analyzing cells from a patient's sputum. This graph shows the overall profitability of the lung cancer testing sector, where the development of an accurate and simple test for screening at-risk groups could save many lives and be commercially viable.
Overall market profit
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. The need for such diagnostics is enormous and is not dependent on the economic situation. The company's success is determined by the accuracy of its tests and their implementation in clinical practice. The dynamics in this chart do not affect its core business.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company bioAffinity Technologies
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. Future revenue depends on the successful commercialization of this test and its adoption in clinical practice. This graph reflects analyst expectations regarding the company's potential in early cancer detection.
%20profit%20of%20the%20company%20bioAffinity%20Technologies&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-bioAffinity-Technologies&v=1772567384558 "Graph of future (projected) profit of the company bioAffinity Technologies")
Future (predicted) profit of companies in the market segment - Lungs' cancer
bioAffinity Technologies develops noninvasive tests for the early diagnosis of lung cancer based on sputum analysis. Its technology aims to detect the disease at an early stage, when treatment is most effective. This graph shows revenue projections for the lung cancer diagnostics sector, helping to assess the potential of bioAffinity's technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Lungs-cancer&v=1772567384621 "Graph of future (predicted) profits of companies in a market segment - Lungs' cancer")
Future (predicted) profit of the market as a whole
bioAffinity Technologies develops noninvasive tests for the early detection of lung cancer. Demand for its products depends on healthcare spending and the implementation of screening programs. This economic outlook influences healthcare system budgets and their focus on preventive care.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772567384631 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - bioAffinity Technologies
bioAffinity Technologies is developing non-invasive tests for the early detection of lung cancer. At the commercialization stage, revenue is a key indicator of success. This chart shows how investors assess the test's potential to transform screening for this deadliest form of cancer.
P/S market segment - Lungs' cancer
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer. Their first product targets lung cancer and uses sputum analysis, which could significantly simplify and reduce the cost of screening for at-risk groups. This chart reflects the average revenue estimate for the sector, helping to assess the market's perception of the potential of this important diagnostic technology.
P/S of the market as a whole
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. This chart highlights that the valuation of such diagnostic companies depends on the potential of their technology to save lives and reduce healthcare costs, which the market can place very high values on.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company bioAffinity Technologies
bioAffinity Technologies develops non-invasive tests for the early detection of cancer, starting with lung cancer. Its technology uses sputum analysis. Estimating future revenue for such a diagnostic company is critical. It reflects investors' belief that its test will become a widely used screening tool, opening up a huge market and the potential to save lives.
%20P%2FS%20bioAffinity%20Technologies&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-bioAffinity-Technologies&v=1772567384700 "The graph of the company's future (projected) P/S bioAffinity Technologies")
Future (projected) P/S of the market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive diagnostic tests for the early detection of cancer, starting with lung cancer. This chart compares the company's estimated future sales with expectations for the medical diagnostics sector. It shows whether investors believe its sputum-based test will become a valuable screening tool for high-risk groups.
%20P%2FS%20market%20segment%20graph%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Lungs-cancer&v=1772567384711 "Future (projected) P/S market segment graph - Lungs' cancer")
Future (projected) P/S of the market as a whole
bioAffinity Technologies is developing a noninvasive test for the early detection of lung cancer using sputum analysis. The company's success is entirely dependent on the commercialization of this product. This graph of investor expectations reflects their belief that diagnostic breakthroughs can save millions of lives and generate enormous revenue.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772567384713 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales bioAffinity Technologies
This chart shows bioAffinity Technologies' revenue from its core product—a noninvasive sputum-based test for the early detection of lung cancer. Revenue growth will depend directly on successful commercialization, insurance coverage, and acceptance by the medical community.
Sales of companies in the market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive tests for the early detection of cancer. Its first product targets lung cancer. As it commercializes, its revenue breakdown will reflect revenue from sales of this diagnostic test, demonstrating the potential of its technology to save lives through early detection.
Overall market sales
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. The need for early diagnosis is enormous and unaffected by economic cycles. This general economic graph is irrelevant to the company, whose mission is to save lives by making cancer diagnosis simpler and more accessible for high-risk groups.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company bioAffinity Technologies
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer, primarily lung cancer, by analyzing sputum samples. Revenue growth depends on the commercialization of its CyPath Lung test. This chart shows analysts' expectations for demand for safe and effective lung cancer screening methods in high-risk groups.
%20sales%20of%20the%20company%20bioAffinity%20Technologies&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-bioAffinity-Technologies&v=1772567384745 "Schedule of future (projected) sales of the company bioAffinity Technologies")
Future (projected) sales of companies in the market segment - Lungs' cancer
bioAffinity Technologies is developing non-invasive tests for the early detection of lung cancer. This chart illustrates the forecast for the medical testing market. Is demand for highly accurate and easy-to-use screening tests for high-risk groups growing? This determines the overall outlook for the diagnostics industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Lungs-cancer&v=1772567384748 "Schedule of future (projected) sales of companies in the market segment - Lungs' cancer")
Future (projected) sales of the market as a whole
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. Demand for such diagnostics is driven by screening programs, physician recommendations, and healthcare systems. This timeline is minimal, as early cancer detection is a global healthcare priority in any economic situation.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772567384751 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality bioAffinity Technologies
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer, particularly lung cancer, using sputum analysis. This chart shows the company's financial trajectory during the commercialization phase. Profitability depends on widespread adoption of the test, obtaining insurance coverage, and demonstrating its accuracy and cost-effectiveness.
Market segment marginality - Lungs' cancer
bioAffinity Technologies, Inc. develops noninvasive diagnostic tests for the early detection of cancer, beginning with lung cancer. This chart reflects the company's financial performance during the development and commercialization phases, where profitability depends on the successful launch of its tests and their acceptance by the medical community.
Market marginality as a whole
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. The company aims to improve the diagnosis of one of the most deadly diseases. This overall profitability chart reflects the state of the healthcare system and its willingness to invest in preventive medicine, which could reduce costs in the future.
Employees in the company, segment and market as a whole
Number of employees in the company bioAffinity Technologies
bioAffinity Technologies develops noninvasive tests for the early detection of lung cancer. Its team of scientists and technicians is its greatest asset. This chart shows how the company is expanding its resources to conduct clinical trials and prepare for the commercial launch of its first diagnostic product, based on sputum analysis.
Share of the company's employees bioAffinity Technologies within the market segment - Lungs' cancer
bioAffinity Technologies develops non-invasive methods for early cancer diagnosis, beginning with lung cancer. Its activities are focused on scientific research and clinical trials. This graph shows the company's market share in the biotech sector, which is an indicator of the scale of its research program and R&D team.
Number of employees in the market segment - Lungs' cancer
bioAffinity Technologies is developing noninvasive diagnostic tests for the early detection of lung cancer through sputum analysis. The chart shows employment in the lung cancer testing sector. A simple and accurate test could save many lives, as lung cancer is often diagnosed in its later stages, when treatment is less effective.
Number of employees in the market as a whole
bioAffinity Technologies develops non-invasive methods for early lung cancer diagnosis. This is a critically important area of medicine. The company's growth is determined not by economics, but by successes in research and clinical trials. Given the overall picture in this chart, bioAffinity represents a sector where employment is an investment in saving lives.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company bioAffinity Technologies (BIAF)
bioAffinity Technologies develops noninvasive diagnostic tests for the early detection of cancer, particularly lung cancer (CyPath Lung). It is an R&D-driven medtech company. This chart shows how the market values their IP. It reflects the market value per employee, which is a measure of the value of their diagnostic platform.
%20of%20the%20company%20bioAffinity%20Technologies%20(BIAF)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-bioAffinity-Technologies-BIAF&v=1772567384852 "Chart of market capitalization per employee (in thousands of dollars) of the company bioAffinity Technologies (BIAF)")
Market capitalization per employee (in thousands of dollars) in the market segment - Lungs' cancer
bioAffinity Technologies (BIAF) is developing a noninvasive test for the early detection of lung cancer based on sputum analysis. In the field of oncology diagnostics, this graph represents a significant life-saving potential. The very high capitalization per employee suggests that their test has the potential to revolutionize lung cancer screening, the deadliest form of cancer.
%20by%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Lungs-cancer&v=1772567384854 "Market capitalization per employee (in thousands of dollars) by market segment - Lungs' cancer")
Market capitalization per employee (in thousands of dollars) for the overall market
bioAffinity Technologies develops non-invasive tests for the early detection of lung cancer. The company's value lies in its unique technology. The graph shows a high employee rating, as a successful and easy-to-use test for the deadliest type of cancer will be a major breakthrough in medicine and a multi-billion dollar market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772567384875 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company bioAffinity Technologies (BIAF)
bioAffinity Technologies is a company developing noninvasive tests for the early detection of cancer, primarily lung cancer (the CyPath test). This graph shows the company's commercialization stage. A loss per employee represents the R&D phase, while a profit would represent the successful launch of the test.
%20Chart%20bioAffinity%20Technologies%20(BIAF)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-bioAffinity-Technologies-BIAF&v=1772567384877 "Company Profit Per Employee (in thousands of dollars) Chart bioAffinity Technologies (BIAF)")
Profit per employee (in thousands of dollars) in the market segment - Lungs' cancer
bioAffinity Technologies, Inc. develops non-invasive methods for the early detection of lung cancer. In this critically important area of medicine, the efficiency per employee reflects the potential of their technology to save lives and generate revenue. The graph shows the financial return per research team, which is an indicator of the commercial viability of their developments.
%20in%20the%20market%20segment%20-%20Lungs'%20cancer&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Lungs-cancer&v=1772567384890 "Chart of profit per employee (in thousands of dollars) in the market segment - Lungs' cancer")
Profit per employee (in thousands of dollars) for the market as a whole
bioAffinity Technologies is a biotech company focused on early lung cancer diagnosis using sputum analysis (the CyPath test). It operates in both R&D and laboratory diagnostics. This chart, showing average market efficiency, helps to understand the contrast with R&D businesses, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772567384892 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee bioAffinity Technologies (BIAF)
bioAffinity Technologies is developing non-invasive tests for the early detection of lung cancer. This graph shows the path to commercialization of their technology. A sharp increase in revenue per employee will indicate the successful launch of their test, enabling a small scientific team to generate significant revenue and save lives.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-bioAffinity-Technologies-BIAF&v=1772567384894 "Sales chart per company employee bioAffinity Technologies (BIAF)")
Sales per employee in the market segment - Lungs' cancer
bioAffinity Technologies (BIAF) is a medical technology company developing noninvasive tests for the early detection of cancer, specifically lung cancer (Cypath Lung) using sputum analysis. This graph shows the average output in the sector. For BIAF, this is an indicator of how productive their R&D and commercial teams are in advancing this diagnostic test.
Sales per employee for the market as a whole
bioAffinity Technologies is developing a noninvasive diagnostic test (Cypath) for the early detection of lung cancer. Their business is comprised of R&D and laboratory diagnostics. This indicator demonstrates how effective their research-intensive model is in converting analyses (collected samples) into commercial revenue.
Short shares by company, segment and market as a whole
Shares shorted by company bioAffinity Technologies (BIAF)
bioAffinity (BIAF) is developing a noninvasive test (sputum analysis) for the early detection of lung cancer. This chart shows the volume of bearish bets. "Shorts" reflect a bet that the company's test will not be accurate enough to replace or complement CT scanning.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-bioAffinity-Technologies-BIAF&v=1772567385005 "Short Shares Chart for the Company bioAffinity Technologies (BIAF)")
Shares shorted by market segment - Lungs' cancer
bioAffinity Technologies (BIAF) is developing non-invasive tests (sputum analysis) for the early detection of lung cancer. This chart shows the total short position in the medical diagnostics sector. It reflects investor skepticism regarding competition with existing methods (CT) and the risks of FDA approval.
Shares shorted by the overall market
bioAffinity Technologies is developing tests for the early detection of lung cancer. This is an R&D project. This chart illustrates the overall market pessimism. When investors are fearful, they are unwilling to fund long R&D cycles. They see a "cash burn" and fear that the product will not be approved or will not be in demand.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator bioAffinity Technologies (BIAF)
bioAffinity Technologies is developing a noninvasive test (sputum analysis) for the early detection of lung cancer. It's a breakthrough technology. This graph measures the "temperature" of hope. It "overheats" with any positive data on the accuracy of their test and "cools" during the long wait for FDA approval.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-bioAffinity-Technologies-BIAF&v=1772567385082 "RSI 14 indicator chart for the company's stock bioAffinity Technologies (BIAF)")
RSI 14 Market Segment - Lungs' cancer
bioAffinity (BIAF) is solving one of the key challenges in oncology: early detection of lung cancer. They are developing noninvasive tests (sputum analysis) that can save lives. This chart tracks the collective "pulse" of the entire Cancer Testing sector. It helps investors understand whether BIAF's dynamics reflect their data or whether the entire industry is overheated or oversold.
RSI 14 for the overall market
For bioAffinity (BIAF), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the cash spigot is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BIAF (bioAffinity Technologies)
bioAffinity Technologies is a diagnostics company. Its flagship product, CyPath Lung, is a noninvasive test (sputum analysis) for the early detection of lung cancer. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the commercial success and clinical adoption of this test.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BIAF-bioAffinity-Technologies&v=1772567385108 "A chart showing analyst consensus forecasts for the expected stock price. BIAF (bioAffinity Technologies)")
The difference between the consensus estimate and the actual stock price BIAF (bioAffinity Technologies)
bioAffinity is a diagnostic company developing CyPath, a noninvasive sputum test for the early detection of lung cancer in smokers. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the implementation of this important screening test.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BIAF-bioAffinity-Technologies&v=1772567385130 "A chart showing the difference between the consensus forecast and the actual stock price. BIAF (bioAffinity Technologies)")
Analyst consensus forecast for stock prices by market segment - Lungs' cancer
bioAffinity (BIAF) is a diagnostic company that developed CyPath, a noninvasive sputum test for the early detection of lung cancer. This chart shows general expectations for the lung oncology sector. It reflects whether experts believe the market for screening tests for high-risk groups will grow.
Analysts' consensus forecast for the overall market share price
bioAffinity Technologies is a company specializing in early cancer detection. Their flagship product is a noninvasive test (sputum analysis) for lung cancer screening. This chart shows overall market sentiment. For bioAffinity, which operates in the "defensive" healthcare sector, overall optimism is important, but their growth depends more on the test's acceptance by insurance companies and physicians.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index bioAffinity Technologies
bioAffinity is a diagnostic tool for lung cancer. Their signature product is CyPath, a noninvasive sputum test that uses AI and flow cytometry for the early detection of lung cancer in smokers. This chart summarizes their implementation history, reflecting their (slow) commercial launch and their (critical) path to Medicare reimbursement.
AKIMA Market Segment Index - Lungs' cancer
bioAffinity Technologies (BIAF) makes cancer visible. Their diagnostic technology (Cypath) is essentially a fluorescent dye that adheres specifically to cancer cells (for example, lung cancer cells) in sputum samples, making them visible under a microscope. This graph shows the average index for the segment, helping to assess the success of this visual diagnostic.
The AKIM Index for the overall market
bioAffinity Technologies is a biotech company that has developed a non-invasive test (CyPath Lung) for the early detection of lung cancer. This chart, which reflects the market average, is a backdrop. It helps assess how bioAffinity Technologies, a diagnostics startup, compares to overall macroeconomic trends in healthcare.
